Investors in Lexicon Pharmaceuticals, Inc. (LXRX - Get Report) saw new options begin trading this week, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the LXRX options chain for the new December 15th contracts and identified one put and one call contract of particular interest.The put contract at the $10.00 strike price has a current bid of 45 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $10.00, but will also collect the premium, putting the cost basis of the shares at $9.55 (before broker commissions). To an investor already interested in purchasing shares of LXRX, that could represent an attractive alternative to paying $10.69/share today. Because the $10.00 strike represents an approximate 6% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 66%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.50% return on the cash commitment, or 31.56% annualized — at Stock Options Channel we call this the YieldBoost. Below is a chart showing the trailing twelve month trading history for Lexicon Pharmaceuticals, Inc., and highlighting in green where the $10.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $11.00 strike price has a current bid of 55 cents. If an investor was to purchase shares of LXRX stock at the current price level of $10.69/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $11.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 8.04% if the stock gets called away at the December 15th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if LXRX shares really soar, which is why looking at the trailing twelve month trading history for Lexicon Pharmaceuticals, Inc., as well as studying the business fundamentals becomes important. Below is a chart showing LXRX's trailing twelve month trading history, with the $11.00 strike highlighted in red: Considering the fact that the $11.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 51%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 5.14% boost of extra return to the investor, or 36.08% annualized, which we refer to as the YieldBoost. The implied volatility in the put contract example, as well as the call contract example, are both approximately 56%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 253 trading day closing values as well as today's price of $10.69) to be 42%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
More from Stocks
Netflix, Bank of America, Opioid Settlement, Brexit, MGM- 5 Things You Must Know
U.S. stock futures decline as Wall Street awaits another round of third-quarter earnings reports and global stocks trade mixed as investors monitored Brexit developments; Netflix, IBM and Bank of America report earnings Wednesday; McKesson, AmerisourceBergen and Cardinal Health reportedly are in talks to pay $18 billion to settle thousands of opioid-related lawsuits.
Johnson & Johnson Gains On Opioid Settlement Reports; Distribution Firms Surge
Johnson & Johnson extended gains in pre-market trading Wednesday amid reports it could be close to agreeing a multi-billion dollar settlement with state attorneys general over its role in the nation's opioid crisis.
J&J, Morgan Stanley, Coca-Cola and More - Biggest Earnings for This Week
Here's list of key companies reporting earnings the week of October 14, 2019.
Is a Bear Market Upon Us? Jim Cramer Will Reveal What Investors Needs to Know
What do you do in a bear market? Are we in a bear market? Jim Cramer will be breaking it down in his next members-only Action Alerts PLUS conference call on Wednesday, October 16 at 11:45 a.m. ET.